Agilent Technologies Inc vs Kimberly Clark Corp — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Kimberly Clark Corp trades at $108.57 (market cap $36.48B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.67%). Which is the better fit depends on your goals.
| A | KMB | |
|---|---|---|
Market Cap | $42.00B | $36.48B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $134.81 |
52-Week Low | $110.24 | $93.05 |
Enterprise Value | $43.55B | $42.04B |
Dividend Yield | 0.69% | 4.67% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Kimberly-Clark (KMB) trades at $109.68, up 0.94% with a bullish technical signal. The stock shows strong profitability with 11.79% net margin and 129.43% ROE, though Q2 2026 earnings missed estimates. Recent news highlights China market challenges and dividend stability. Current valuation metrics include P/E of 21.68 and P/S of 2.2, with analyst consensus price target of $113.20 suggesting modest upside potential from current levels.
KMB presents a balanced investment case with solid fundamentals offset by near-term headwinds. The company maintains strong brand positioning and dividend consistency, but faces execution risks from China market disruptions and consumer softness. Wall Street maintains cautious optimism with 61% hold ratings, indicating potential for gradual appreciation if operational challenges are managed effectively.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →